Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Zimbabwe: Access to anti-retroviral drugs, male

Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
22.9%
in 2024
Zimbabwe
89.0%
in 2024
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
18th
Zimbabwe rank
17th

Access to anti-retroviral drugs, male over time

  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
  • Zimbabwe
020406080100200020122024

How they compare

Zimbabwe currently reports 89.0% against 22.9% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 66.1%.

That makes Zimbabwe's figure about 3.9 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

The two have swapped places 1 time across 25 shared years of data; in 2000 it was Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ahead.

Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th and Zimbabwe ranks 17th of 19 groups.

Zimbabwe has averaged higher in every one of the 3 decades both report.

Head to head by decade

Decade Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Zimbabwe Difference Ahead
2000s 3.3% 4.1% 0.8% Zimbabwe
2010s 10.3% 52.9% 42.6% Zimbabwe
2020s 19.4% 88.4% 69.0% Zimbabwe

Averages of every year both report within each decade.

Frequently asked questions

Which has higher access to anti-retroviral drugs, male, Middle East, North Africa, Afghanistan & Pakistan (excluding high income) or Zimbabwe?
Zimbabwe, at 89.0% against 22.9% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
What is the difference in access to anti-retroviral drugs, male between Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Zimbabwe?
66.1%, with Zimbabwe ahead.
How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Zimbabwe?
25 years are reported by both, from 2000 to 2024.
How do Middle East, North Africa, Afghanistan & Pakistan (excluding high income) and Zimbabwe rank globally for access to anti-retroviral drugs, male?
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th and Zimbabwe ranks 17th of 19 groups.
Where does this data come from?
UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Zimbabwe: Access to anti-retroviral drugs, male. Statizoid, drawing on UNAIDS estimates. Retrieved 19 September 2026, from https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-male-percent/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/zimbabwe/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-male-percent/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/zimbabwe/">Middle East, North Africa, Afghanistan & Pakistan (excluding high income) vs Zimbabwe: Access to anti-retroviral drugs, male</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.